Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial.
Por:
Barrueco ÁS, Mateos-Moreno MV, Martínez-Beneyto Y, García-Vázquez E, González AC, Ferrero JZ, Castaño AB, Rueda IA, Villacampa Aubá JM, Español CC, Moreno-Parrado L, Ausina-Márquez V, García-Esteban S, Artacho A, Xavier López-Labrador F, Mira A and Ferrer MD
Publicada:
1 dic 2022
Ahead of Print:
7 jul 2022
Resumen:
ABSTRACTBackground: In vitro studies have shown that several oral antiseptics have virucidal activity against SARS-CoV-2. Thus, mouthwashes have been proposed as an easy to implement strategy to reduce viral transmission. However, there are no data measuring SARS-CoV-2 viability after mouthwashes in vivo. METHODS: In this randomized double-blind, five-parallel-group, placebo-controlled clinical trial, SARS-CoV-2 salivary viral load (by quantitative PCR) and its infectious capacity (incubating saliva in cell cultures) have been evaluated before and after four different antiseptic mouthwashes and placebo in 54 COVID-19 patients. RESULTS: Contrary to in vitro evidence, salivary viral load was not affected by any of the four tested mouthwashes. Viral culture indicated that cetylpyridinium chloride (CPC) significantly reduced viral infectivity, but only at 1-hour post-mouthwash. CONCLUSION: These results indicate that some of the mouthwashes currently used to reduce viral infectivity are not efficient in vivo and, furthermore, that this effect is not immediate, generating a false sense of security.Trial registration: ClinicalTrials.gov identifier: NCT04707742..
Filiaciones:
Barrueco ÁS:
ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid (Spain)
ENT and Cervicofacial Surgery Department, Villalba General University Hospital, Collado Villalba (Spain)
Mateos-Moreno MV:
Department of Dental Clinical Specialties. School of Dentistry. Madrid Complutense University, Madrid (Spain)
Martínez-Beneyto Y:
Department of Dermatology, Stomatology and Radiology. University of Murcia (SPAIN), Murcian Institute of Biosanitary Research (IMIB), Murcia (SPAIN)
García-Vázquez E:
Infectious Diseases Unit, Virgen de la Arrixaca University Clinical Hospital, IMIB, Murcia (Spain)
González AC:
ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid (Spain)
Ferrero JZ:
Microbiology Department. Fundación Jiménez Díaz University Hospital, Madrid (Spain)
and Villalba General University Hospital, Collado Villalba (Spain)
Castaño AB:
ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid (Spain)
Rueda IA:
ENT and Cervicofacial Surgery Department, Villalba General University Hospital, Collado Villalba (Spain)
Villacampa Aubá JM:
ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid (Spain)
Español CC:
ENT and Cervicofacial Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid (Spain)
Moreno-Parrado L:
Microbiology Service. Murcian Institute of Biosanitary Research. Virgen de la Arrixaca University Clinical Hospital, Murcia (Spain)
Ausina-Márquez V:
Department of Dentistry, European University of Valencia (Spain)
:
Genomics & Health Department, FISABIO-Public Health Foundation, Valencia (Spain)
:
Genomics & Health Department, FISABIO-Public Health Foundation, Valencia (Spain)
:
Genomics & Health Department, FISABIO-Public Health Foundation, Valencia (Spain)
Department of Microbiology and Ecology, Medical School, University of Valencia (Spain)
CIBER in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid (Spain)
:
Genomics & Health Department, FISABIO-Public Health Foundation, Valencia (Spain)
CIBER in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid (Spain)
:
Genomics & Health Department, FISABIO-Public Health Foundation, Valencia (Spain)
Green Published
|